Key Highlights
- Tracey Marantal appointed President of Oncology Business Unit at Worldwide Clinical Trials.
- Brings over 15 years of oncology-focused expertise in small/large molecule research.
- Marantal’s leadership enhances Worldwide’s tailored, patient-centric clinical trial solutions.
- Extensive experience in precision oncology, diagnostics, and biomarkers.
- Strengthens Worldwide’s collaborative partnerships with biopharma sponsors.
Source: Business Wire
Notable Quotes
- “Tracey’s extensive experience in small and large molecule as well as precision oncology, like diagnostics and biomarkers, combined with her expertise in navigating complex trial designs and regulatory landscapes, makes her a tremendous asset to Worldwide.” — Dave Bowser, Chief Operating Officer at Worldwide Clinical Trials
- “I am thrilled to join Worldwide and to be part of a team that is dedicated to pushing the boundaries of oncology research in support of its customers and patients.” — Tracey Marantal, President of Oncology Business Unit at Worldwide Clinical Trials
SoHC's Take
Tracey Marantal’s appointment as President of the Oncology Business Unit at Worldwide Clinical Trials marks a strategic milestone in the CRO’s commitment to advancing cancer research. With her deep expertise in oncology, spanning from small and large molecules to precision oncology, Marantal is poised to lead the organization during a time of significant innovation in cancer treatments. This move solidifies Worldwide’s leadership in oncology trials, providing sponsors with specialized, adaptable solutions that align with the evolving demands of cancer research and patient-centric trials.
